Compatibility of Evolutionary Responses to Constituent Antibiotics Drive Resistance Evolution to Drug Pairs

Leonie Johanna Jahn, Daniel Simon, Mia Jensen, Charles Bradshaw, Mostafa Mostafa Hashim Ellabaan, and Morten Otto Alexander Sommer*

Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark

*Corresponding author: E-mail: msom@bio.dtu.dk.
Associate editor Tal Pupko

Abstract

Antibiotic combinations are considered a relevant strategy to tackle the global antibiotic resistance crisis since they are believed to increase treatment efficacy and reduce resistance evolution (WHO treatment guidelines for drug-resistant tuberculosis: 2016 update.). However, studies of the evolution of bacterial resistance to combination therapy have focused on a limited number of drugs and have provided contradictory results (Lipsitch, Levin BR. 1997; Hegreness et al. 2008; Munck et al. 2014). To address this gap in our understanding, we performed a large-scale laboratory evolution experiment, adapting eight replicate lineages of Escherichia coli to a diverse set of 22 different antibiotics and 33 antibiotic pairs. We found that combination therapy significantly limits the evolution of de novo resistance in E. coli, yet different drug combinations vary substantially in their propensity to select for resistance. In contrast to current theories, the phenotypic features of drug pairs are weak predictors of resistance evolution. Instead, the resistance evolution is driven by the relationship between the evolutionary trajectories that lead to resistance to a drug combination and those that lead to resistance to the component drugs. Drug combinations requiring a novel genetic response from target bacteria compared with the individual component drugs significantly reduce resistance evolution. These data support combination therapy as a treatment option to decelerate resistance evolution and provide a novel framework for selecting optimized drug combinations based on bacterial evolutionary responses.

Key words: adaptive evolution, antimicrobial resistance, combination therapy.
In order to address this lack of knowledge, we conducted a systematic high-throughput adaptive laboratory evolution (ALE) experiment for *Escherichia coli*, an important model organism and human pathogen (Bodilsen et al. 2018). The large number of replicate lineages and the broad range of drugs tested combined with a systematic assessment of the evolvability allowed us to analyze the phenotypic and genotypic evolutionary responses to single and combinatorial drug exposure. Based on this comprehensive dataset we identified for the first time distinct patterns in the genetic responses towards drug combinations. Moreover, these genetic trajectories are reliable predictors for the evolvability of antibiotic resistance.

**Results**

**Resistance Evolution towards a Diverse Set of Antibiotic Combinations**

To identify the underlying features that drive the evolution of resistance to combination therapy, we adapted genetically barcoded replicate lineages (Jahn et al. 2018) of the well-studied model organism *E. coli* k12 MG1655 to a diverse set of 22 different antibiotics and 33 different antibiotic pairs (supplementary tables S1 and S2, Supplementary Material online). These drugs, including both bactericidal (68.18%) and bacteriostatic (31.81%) drugs, covered 11 different drug classes and targeted 6 different bacterial processes (supplementary table S2, Supplementary Material online, fig. 1a).

Moreover, we assessed the phenotypic features of the drug pairs. First, we classified the drug combinations based on the drug interaction and found that they covered all three possible drug interactions: synergistic (34.4%), additive (28.1%), and antagonistic (37.5%) (fig. 1b). The classification was done by measuring the drug concentration that resulted in a 90% growth-reduction (IC$_{90}$) of the wild type (WT) compared with WT growth in media only for all single antibiotics and for the antibiotics in combination. Based on these values the fractional inhibitory concentration index was calculated (FICI) (Tyers and Wright 2019). While different methods to calculate drug interactions are used that impact the classification of drug interactions, we decided to use a Loewe-additivity model based on the IC$_{90}$ (which is similar to the minimal inhibitory concentration [MIC]) as this commonly reported in scientific studies and allows best possible comparison of our study with the existing literature (Munck et al. 2014; Gonzales et al. 2015; Stokes et al. 2017; Minato et al. 2018; Tyers and Wright 2019). Further, we defined cut-offs for the FICI (Materials and Methods) to distinguish between the drug interactions: antagonistic (ANT, FICI > 1.5), additive (ADD, FICI = 0.75–1.5), and synergistic (SYN, FICI < 0.75).

Resistance to these drugs and drug combinations was achieved via ALE (Jahn et al. 2017). Even though adaptive evolution experiments simplify the growth conditions in human hosts, they can capture clinically relevant features of resistance evolution (Imamovic et al. 2018). In addition, adaptive evolution reduces the complexity of resistance evolution in clinical settings and allows studying specific parameters systematically under controlled conditions (Jansen et al. 2013). We performed the evolution experiment in a stepwise manner (Jahn et al. 2017), in eight biological replicate lineages giving a total of 460 lineages (including 20 LB-only controls) (fig. 1c, methods, antibiotic concentrations in supplementary table S3, Supplementary Material online). A single isolated colony was obtained for each revived endpoint lineage for subsequent genotypic and phenotypic characterizations (supplementary table S4, Supplementary Material online).

After the adaptive evolution experiment, we measured the IC$_{50}$ of all isolates. In order to check whether the isolates were representative for the lineage they were obtained from, we calculated the difference between the IC$_{50}$ of the lineages and the IC$_{50}$ of the isolates derived from the respective lineages and normalized it by the lineage IC$_{50}$ similar to the calculation of the Coefficient of variance (CV). The median of these indices was 0.66 indicating an acceptable agreement between isolates and lineage IC$_{50}$. However, certain antibiotics like beta-lactams and many drug combinations had higher or lower lineage resistance compared with the isolates (supplementary fig. S1, Supplementary Material online). This might be the result of different aspects, such as population dynamics (Lee et al. 2010), inoculum effect (Brook 1989), tolerance (Levin-Reisman et al. 2017), and selection bias of the isolates due to freezing sensitivity (Barbosa and Levy 2000).

We also measured the IC$_{50}$ of all isolates adapted to single-drugs towards all single drugs used. The resulting data allowed us to assess collateral drug responses (supplementary fig. S2, Supplementary Material online). Therefore, the drug pairs could be grouped based on the collateral IC$_{50}$ change index into one of three categories: collateral resistant (CR, collateral IC$_{50}$ change index > 2), collateral sensitive (CS, collateral IC$_{50}$ change index < 0.5), or neutral (N, collateral IC$_{50}$ change index 0.5–2). The collateral IC$_{50}$ change index provides the average change in fold resistance relative to the WT between two isolates adapted to either drug A or B to the respective other drug (Munck et al. 2014). We found that the drug pairs displayed all possible collateral responses between the individual drugs constituting the pairs (fig. 1b).

**Assessment of Evolutionary Responses to Combination Therapy**

Before we analyzed the isolates, we also observed the behavior of the entire populations during the adaptive evolution experiment. A majority (68.4%) of the lineages adapted to monodrug exposure exhibited stable growth throughout the evolution experiments (chi-square test of independence, $X^2 = 84.742$, $P = 2.2e-16$, df = 1, $n$(Mono) = 152, $n$(Combination) = 256). In contrast, most (59.4%) of the lineages exposed to drug combinations exhibited declining OD values over time (chi-square test of independence, $X^2 = 37.028$, $P = 1.164e-09$, df = 1, $n$(Mono) = 152, $n$(Combination) = 256) (supplementary fig. S3a–c, Supplementary Material online). Declining OD values might indicate that the populations did not evolve resistance at a sufficient pace to ensure survival. Further, we measured the resistance level of the lineages at different time points during the experiment. We calculated the CV of the endpoint IC$_{50}$ levels of the parallel-evolved lineages and found a significant...
Mann–Whitney U-test, $P = 0.003076$, $U = 2552$, two-sided, confidence level $= 0.95$) difference between the variance of single-drug (CV = 0.388417) and drug pair (CV = 0.6410415) evolved lineages. Usually, a higher degree of phenotypic convergent evolution is associated with a higher selection pressure and constrained evolution (MacPherson and Nuismer 2017), yet parallel evolution is also highly depended on population size (Bailey et al. 2015). As mentioned before drug pair evolved lineages had often decreasing population.
sizes, which might account for the higher phenotypic variability.

Looking at the IC90 data of the lineages during the evolution experiment, we found that after completion of the evolution a majority (67.8%) of the drug-pair-evolved replicate lineages, but a minority (23.5%) of the single-drug-evolved lineages, only gained resistance levels below the antibiotic concentration they were exposed to during the ALE (chi-square test of independence, $X^2 = 73.117, P = 2.2e{-16}$, df = 1, $n$(Mono) = 152, $n$(Combination) = 256) (supplementary fig. S3d–f, Supplementary Material online). This observation suggests a limited capacity of drug-pair-exposed lineages to evolve resistance.

**Combination Therapy Reduces Resistance Evolution**

To further examine resistance evolution we assessed the phenotypes of the isolated colonies from the end point of the evolution experiment. We found that isolates evolved to about half of the drug pairs (15) displayed resistance to the drug pair and the individual drugs constituting the pair. For the other drug combinations we observed resistance to the drug pair and only one of the individual drugs (eight drug pairs), only to one of the individual drugs (five drug pairs) or no resistance at all (four drug pairs).

This observation highlights variable abilities to evolve resistance and different dynamics of the drug pairs to select for adaptations.

To shed light on the factors that impact resistance evolution, we calculated the evolvability index for all drug pair-evolved lineages (Munck et al. 2014). The evolvability index describes the final phenotypic adaptation level relative to single-drug-evolved isolates (Munck et al. 2014). All the isolates except those evolved to a combination of ciprofloxacin and azithromycin had a median evolvability index $<1$, indicating that the drug-pair-evolved isolates became less resistant to the two individual drugs than the isolates evolved to these drugs alone (fig. 2). In fact, for a majority of the drug pairs (87.5%), very limited resistance evolution was observed (evolvability index $<0.5$).

These findings highlight that drug pairs in general reduce the adaptive potential of de novo de novo antibiotic resistance evolution in *E. coli*. Nevertheless, *E. coli* evolved resistance to specific drug combinations to a markedly different degree.

**Phenotypic Features Impact Evolvability Only Marginally**

Prior studies have suggested that drug features like synergistic or antagonistic drug interactions or collateral drug responses play an important role in explaining the difference in resistance evolution toward drug combinations (Hegreness et al. 2008; Munck et al. 2014; Suzuki et al. 2015; Barbosa et al. 2018) (fig. 3a). We grouped the drug pairs into antagonistic, additive and synergistic based on the FICI. However, we observed only a minor contribution of synergistic or antagonistic drug interactions on the evolvability of resistance (fig. 3b). Further, we did not find a correlation between the FICI and the evolvability index (fig. 3c). Next, we assessed the effect of collateral responses on evolution of resistance to drug combinations by grouping the drug pairs based on the collateral IC90 change index. Again, we observed only a limited effect of collateral
responses on the evolvability index (fig. 3d) and no significant correlation between the collateral IC90 change index and the evolvability index (fig. 3e).

Genetic Responses to Drug Pairs Follow Distinct Patterns

To determine the genetic basis of resistance and to assess if the genotypes could explain the varying levels of evolvability among the different drug pairs, we performed whole-genome sequencing on 313 of the phenotypically characterized isolates that exhibited phenotypic resistance (IC90 > 2-fold WT IC90) after an initial screening (supplementary table S6, Supplementary Material online). In total, we found 1,062 single nucleotide variants, 1,052 gene duplications, and 368 insertions or deletions (supplementary table S7, Supplementary Material online). Six isolates displayed a hypermutator phenotype with between 21 and 383 mutations. All hypermutators had a mutation in either mutS, mutT, or mutD (dnaQ) (supplementary table S7, Supplementary Material online), which induce the hypermutator phenotype (Jolivet-Gougeon et al. 2011). On average, we detected \( \frac{6}{5} \) mutations per isolate. The number of mutations per isolate was roughly the same between isolates adapted to a single or to multiple antibiotics (supplementary fig. S4, Supplementary Material online). However, the types of mutations differed. While single nucleotide polymorphisms (SNP) were the dominant response under single drug exposure, gene duplications were most prevalent in drug pair evolved isolates, as reported before (Laehnemann et al. 2014). The gene that was mutated the most \( (101 \text{ times} + 15 \text{ times in the promoter region}) \) was marR (supplementary table S7, Supplementary Material online), the regulator of the multiple antibiotic resistance locus (Cohen et al. 1993), a gene in which mutations can induce a multidrug resistance
phenotype (Woodford and Ellington 2007). Antibiotic resistance is facilitated through MarR by the transcriptional regulation of at least 80 chromosomal genes (Pomposiello et al. 2001; Barbosa and Levy 2000; Alekshun and Levy 1997), involving primarily stress response (Alekshun and Levy 1997) and multidrug efflux (Keeney et al. 2008). Multiple other mutations are also known to be linked to a multidrug resistance phenotype and often involve AcrB-mediated efflux of the antibiotic (Okusu et al. 1996) and have been identified in this study (supplementary table S7, Supplementary Material online). The multidrug resistance induced through these mutations can be illustrated by clustering the antibiotic evolved isolates based on their genetic similarity. We calculated the genetic similarity of all single drug evolved isolates based on the Jaccard’s Distance and found that isolates evolved to different drugs like tetracyclines, chloramphenicol, beta-lactam and macrolide antibiotics clustered together (supplementary fig. S5, Supplementary Material online). This finding highlights that resistance mechanisms evolve that are not necessarily specific to the mechanism of action of the antibiotic. In addition, the genetic similarity can also explain collateral resistance as genetic similarity and collateral resistance are positively correlated (supplementary fig. S6, Supplementary Material online).

We grouped drug-pair-evolved isolates into four distinct genetic responses relative to their genetic response towards their constituent drugs: 1) mutations conferring resistance to both constituent drugs are the same and are selected by the drug combination (Shared genotype); 2) mutations conferring resistance to both constituent drugs are different, yet are both selected by the drug combination (Mixed genotype); 3) mutations conferring resistance to both constituent drugs are different, yet only mutations for one of the constituent drugs are selected by the drug combination (One Drug genotype); or 4) mutations selected by the drug combination are different from those selected by each of the constituent drugs (New genotype) (fig. 4a). To classify the drug pairs into these distinct categories, we performed an analysis of similarities (ANOSIM) based on the mutations of each sequenced isolate (supplementary table S7, Supplementary Material online). ANOSIM is a nonparametric statistical test that is widely used in ecology to identify differences among ecological niches based on ranked dissimilarity matrices (Bueno et al. 2018). Here, we used mutated genes as features to identify differences between various adaptation conditions instead of characteristics of an ecological niche.

The Shared group contained three drug pairs for which no significant genotypic differences (R < 0.2 and/or P > 0.005,
Drug pairs with a Mixed genotype exhibited either neutral or collateral resistance to each other, further highlighting that these drug pairs have compatible genetic responses (Supplementary fig. S7, Supplementary Material online).

The One Drug group was composed of drug pairs where the genotype exclusively resembled that of isolates evolved to one of the individual drugs and contained 14 drug pairs (fig. 4d). For example, mutations selected against amikacin were also present in the isolates exposed to amikacin and chloramphenicol, while none of the mutations found in chloramphenicol-adapted isolates were selected in the drug-pair-evolved isolates. Five drug pairs in the One Drug group reached only final exposure levels around the ID_{50} of the individual drugs, mainly due to synergism (Supplementary fig. S7, Supplementary Material online). This finding indicates that adaptation to highly synergistic drug pairs might be achieved by selection of mutations against one of the constituent drugs thereby possibly shifting the drug interaction profile. This would suggest that synergistic drug combinations could readily loose efficiency if used at insufficient doses, as previously suggested (Lipsitch and Levin 1997; Pena-Miller et al. 2013). Other factors influencing the selection of mutations towards one of the drugs might be differences in the steepness of the dose response curves (Chevereau and Bollenbach 2015) and accordingly different levels of selection.

**Fig. 5.** Drug pairs requiring a novel genetic response compared to the constituent drugs have a significantly lower resistance evolvability. S = Shared genotype; M = Mixed genotype; O = OneDrug genotype; N = New genotype. a The median evolvability index (MAD) of drug combinations grouped by genetic response patterns (Mann-Whitney U-test, median(Shared) = 0.32, n(Shared) = 24, median(Mixed) = 0.8, n(Mixed) = 15, median(OneDrug) = 0.36, n(OneDrug) = 99, median(New) = 0.21, n(New) = 39, Shared- Mixed: p = 0.1308, U = 233, Shared-OneDrug: p = 0.5815, U = 1146, Shared-New: p = 0.008947, U = 291, Mixed-OneDrug: p = 0.0697, U = 997.5, Mixed-New: p = 0.009358, U = 438, OneDrug-New: p = 0.002111, U = 1376, Bonferroni corrected, two-sided, confidence level = 0.05). b Schematic overview of the different drug regimes (single drug A, single drug B and drug pair A and B) and the pool of potentially beneficial mutations that can confer resistance. We hypothesize that the adaptation potential of the Shared and OneDrug groups are comparable to the ones of the individual drugs, maybe slightly smaller due to few genetic constraints. The pool of beneficial mutations of the mixed group might in fact be bigger than the two pools of the single drugs as mutations against both drugs can be selected for. This might explain why the evolvability of drug pair evolved isolates in the mixed group can be higher than the evolvability of single drug evolved isolates. The New group has a much smaller pool of beneficial mutations, as the adaptations against the individual drugs are not compatible, reducing the options for adaptations and therefore the evolvability.

Supplementary table S8, Supplementary Material online) were observed between single-drug-evolved isolates or between single-drug-evolved isolates and drug-pair-evolved isolates (fig. 4b). For example, key mutations found in doxycycline-adapted isolates were also dominant in chloramphenicol-evolved isolates as well as isolates exposed to both drugs simultaneously. All drug pairs belonging to the Shared group exhibited collateral resistance to each other (Supplementary fig. S7, Supplementary Material online), as the genetic alterations provide resistance to both individual drugs as well as to the drug pair.

The Mixed group contained two drug pairs, where a significant difference (R > 0.2 and P < 0.005, Supplementary table S8, Supplementary Material online) between the genotypes of isolates evolved to individual drugs was observed, but no significant difference was observed between the genotypes of drug-pair-evolved isolates and those of isolates evolved to individual drugs (fig. 4c). For example, while the genotypes of isolates evolved to either ciprofloxacin or azithromycin were completely different, the drug-pair-evolved isolates exhibited key mutations that were also found in the isolates exposed to the individual drugs (fig. 4c). This drug combination was also the only one that had a median evolvability index >1, indicating that compatible genetic pathways are unlikely to reduce the evolvability. The two
pressure applied by the two drugs (supplementary fig. S8, Supplementary Material online) as well as differences in the mutation selection window and the ability to select for mutations at subinhibitory concentrations (supplementary fig. S9, Supplementary Material online).

Another five of the drug combinations in the OneDrug group were resistant to both individual drugs and drug pairs. Drugs in these pairs were substrates of the AcrB efflux pump (Yu et al. 2003). While isolates adapted to one of the constituent drugs alone, such as ciprofloxacin, develop resistance primarily via other resistance modes, such as mutations in gyrA, isolates adapted to the other drug, such as doxycycline, select for efflux-enhancing mutations. In combination, the efflux mutations are dominant, as these mutations confer resistance to both drugs simultaneously and are therefore likely to be selected. Consequently, the resulting genotype resembles the genotype of the efflux-mutation-selecting single-drug-evolved isolates, even though a shared resistance mechanism is selected. Of the remaining drug combinations in the OneDrug group, two displayed collateral sensitivity, which might have suppressed resistance evolution to one of the drugs.

The New group included drug pairs for which the ANOSIM gave significant ($R > 0.2, P < 0.005$, supplementary table S8, Supplementary Material online) differences in genotypes between individual drugs and drug pairs (fig. 4e). For example, azithromycin- and trimethoprim-adapted isolates shared almost no mutations, while the isolates evolved to the combination of azithromycin and trimethoprim selected none of these mutations but repeatedly accumulated mutations in the mechanosensitive channel encoding gene mscM. Drug pairs with collateral sensitivity were found only in the OneDrug and New groups (supplementary fig. S7, Supplementary Material online), highlighting that those incompatible genetic trajectories to the individual drugs cannot be co-selected in drug combinations.

**Drug Pairs Requiring Novel Genetic Responses Exhibit the Lowest Evolvability Index**

To assess the impact of genotypic response on phenotypic evolvability, we analyzed the evolvability of the four different genetic groups. Drug pairs in the New group generally showed a lower evolvability index and a lower evolutionary rate (fig. 5a). Of the five drug pairs that composed the New genotype group, three exhibited collateral sensitivity to each other in at least one direction and two were defined collateral sensitive based on the collateral IC$_{90}$ change index. All three contained an aminoglycoside antibiotic (supplementary fig. S7, Supplementary Material online). These drug pairs also had the lowest evolvability indices within the group. However, isolates evolved to azithromycin and trimethoprim also developed a distinct new genotype, despite a lack of collateral sensitivity.

Overall, these findings highlight that drug combinations work best at decelerating resistance evolution when the resistance modes to the individual drugs are incompatible and require a novel genetic response (fig. 5b). There appears to be a low probability of selection of these novel responses, as evolvability in this genetic group was significantly lower than that in the other groups (fig. 5). Interestingly, collateral sensitivity might be an indicator for the genetic incompatibility as drug pairs with collateral sensitivity grouped exclusively in the New and OneDrug group (Pearson’s Chi-squared test, $X^2 = 16.381, P = 0.01195$, df = 6). By contrast, drug pairs that evolved resistance by selecting for mutations against both drugs, belonging either to the Mixed or Shared group and in part to the OneDrug groups, had higher evolvability indices (fig. 5a), demonstrating that combinations of antibiotics that have compatible genetic responses are not well suited to limit resistance evolution.

**Discussion**

This study aimed to assess the potential of antibiotic combinations in reducing resistance evolution and to identify key properties of these combinations that can predict resistance evolution. We observed that de novo novo antibiotic resistance evolution is reduced in *E. coli* when two antibiotics are combined. We further assessed the ability of phenotypic parameters, such as drug interactions and collateral responses to predict the evolvability.

Previous studies reported conflicting abilities of synergistic or antagonistic drug interactions in limiting resistance evolution (Lipsitch and Levin 1997; Hegreness et al. 2008; Torella et al. 2010; Pena-Miller et al. 2013; Munck et al. 2014; Barbosa et al. 2018). In line with Munck et al. (2014), we find that drug interactions are weak predictors for resistance evolution. In addition to drug interactions we also analyzed the impact of collateral drug responses on the evolvability of resistance to drug combinations. Previous work had shown a correlation between collateral sensitivity and limited resistance evolution. However, even though drug pairs with collateral sensitivity had a lower evolvability index as neutral or collateral resistant drug pairs, the difference was not significant. This could be due to the small sample size of collateral sensitive drug pairs or the experimental design that selected for a specific resistance level.

Yet, by systematically analyzing the genetic adaptations, we observed a clear pattern relating the genetic trajectories to resistance evolution. Grouping of drug pairs based on genotypes revealed that resistance evolution to drug pairs that required a new genotypic response relative to the genetic adaptations to the constituent drugs was greatly limited. Future work in identifying further evolutionary constrained drug pairs and a framework to predict limited resistance evolution will be needed in order to identify the best drug combinations for limited resistance evolution.

In general, our data provides a comprehensive resource for the exploration of de novo resistance evolution in *E. coli* and of the different phenotypic and genotypic adaptations to monotherapy and combination therapy. However, the number of isolated colonies for each evolved lineage could be expanded in order to ensure that population heterogeneity and heteroresistance is captured sufficiently in the analysis and additional drug combinations and organisms would need to be characterized to elucidate whether our
findings can be further generalized. In addition, the impact of drug combinations on the evolution of antibiotic tolerance should be addressed in future work. Moreover, it remains to be determined whether our findings can be translated to the clinic. Adaptive evolution is frequently used to explore the response to antibiotic exposure (Imamovic and Sommer 2013; Lázár et al. 2013; Munck et al. 2014; Jahn et al. 2017). However, factors, such as horizontal gene transfer, host–pathogen interactions, interactions between bacterial populations, side effects and pharmacodynamics of the antibiotics, as well as patient condition and disease, need to be considered when clinical experiments are conducted. Nonetheless, we expect that this framework for assessment of evolvability of drug combinations will be the base for further research on the rational design of drug combinations for efficient and resistance-limiting therapies.

Materials and Methods

Bacterial Strains and Growth Conditions
Chromosomally barcoded E. coli MG1655 K12 (Jahn et al. 2018) were grown in LB at 37°C and 600 r.p.m. shaking. They were grown under the same conditions without shaking for the IC90 determination.

ALE to Individual Drugs and Drug Combinations
Escherichia coli lineages were evolved each in eight biological replicate lineages to 22 different antibiotics and 33 different antibiotic pairs (supplementary table S1, Supplementary Material online) resulting in 460 individual lineages of which all E. coli lineages carried a unique genetic barcode (Jahn et al. 2018). Barcodes allowed to track lineages and to ensure that no cross-contamination between replicates took place. Moreover, genetically adapted lineages with barcodes can be provided as a valuable resource for additional experiments. All antibiotics used in this study, their mechanism of action, solvent and storage conditions are listed in supplementary table S2, Supplementary Material online. For the evolution towards drug combinations, the drugs were combined in a 1:1 ratio based on the WT IC90 values of the individual drugs (Munck et al. 2014). The WT was exposed to a dilution series of the drug mixture, the IC90 of the drug combination was established and used as a reference to define the antibiotic concentrations used for the adaptive evolution experiment (supplementary table S3, Supplementary Material online). The antibiotic pairs were chosen to cover the most important drug classes (beta-lactams, fluoroquinolones, aminoglycosides, macrolides, tetracyclines, chloramphenicol, and peptide antibiotics) in all their possible combinations, to include drug pairs of drugs from the same drug classes and some additional drug pairs so that we could cover all possible drug interactions and collateral relationships between drug pairs.

The adaptive evolution experiment was carried out in 96-deep-well plates. The plates were filled with LB by a Hamilton robot, sealed and stored at room temperature. Antibiotics were added by the robot the day before the experiment started and plates were stored at −20°C. An overnight culture grown in LB was used to inoculate the ALE experiments. All passaging of cells was done manually with an 8-channel pipette. As a control 20 replicates were evolved to LB media alone. Each 96-well plate also harbored eight negative controls that stayed uncontaminated throughout the evolution experiment. Cells were grown for 22 h at 37°C and 600 r.p.m. shaking, ensuring mixing of the population and aerobic growth conditions (aerobic growth conditions during the evolution can be assumed as genetic adaptations to aminoglycoside antibiotics, whose uptake depends on aerobic respiration, were identified as well as a mutational overlap with other studies that had a greater surface:volume ratio [Munck et al. 2014] or better mixing [Hegreness et al. 2008]). Thereafter, 100 μl were transferred to a 96-well plate and the optical density (OD600) of each lineage was measured in an ELx808 Absorbance Reader (BioTek) at a wavelength of 600 nm. In addition, 50 μl of cells, corresponding to a 20-fold dilution (Wahl et al. 2002; Jahn et al. 2017), were passaged to a new preheated 96-deep-well plate containing LB and a 25% increase in antibiotic concentration in a total volume of 1 ml/well. The starting concentration was 25% of the WT IC90 and the WT IC90 drug concentration was reached on the seventh day of the ALE (supplementary table S3, Supplementary Material online). The evolution was stopped after 18 days at a final concentration exceeding 10-fold of the WT IC90 (Jahn et al. 2017). All antibiotic concentrations can be found in supplementary table S3, Supplementary Material online. The IC90 of the lineages was measured on day 0, 8, 13, and 18 of the ALE in order to track the resistance evolution on the population level.

After each transfer an aliquot of 100 μl was mixed with glycerol to a final glycerol concentration of 12.5% and stored at −80°C. Cells were streaked on LB agar from the frozen aliquot saved on the last day with growth (OD600 > 0.1). Some cells were very difficult to revive as observed before (Barbosa et al. 2017). If reviving failed, cells were inoculated into liquid LB before being streaked on LB agar. If cells still failed to revive, cells were streaked from the aliquot saved the day before the last day of growth. Despite the effort, some lineages would not revive at all. A list with all lineages, their last day of growth in the ALE and the day of the ALE they have been revived from can be found in the supplementary (supplementary table S4, Supplementary Material online). One isolated colony was picked randomly for each evolved lineage, grown in LB and frozen at −80°C for further phenotypic and genotypic characterization. Lineages adapted to the following antibiotics: Erythromycin, Sulfamethoxazole, Fosfomycin as well as the combination of Sulfamethoxazole and Trimethoprim displayed inconsistent phenotypes or did not develop resistance due to technical reasons, such as drug stability after freezing. Therefore, these drugs were excluded from this study.

IC90 Determination
100 μl of LB were inoculated with pin-replicators from frozen stocks of isolated colonies and grown overnight. About 10^5 cells were transferred with pin-replicators into plates containing a 2-fold drug gradient ranging over ten different concentrations. Plates were grown at 37°C for 18 h. The OD600 was
measured for each well. The OD_{600} data were normalized and used to create dose-response curves in R as described before (Munck et al. 2014). In brief, percent inhibition was calculated by the following formula:

\[
1 - \frac{OD_{600 \text{ drug exposed}} - OD_{600 \text{ blank}}}{OD_{600 \text{ media exposed}} - OD_{600 \text{ blank}}}
\]

The IC_{90} was defined as the lowest concentration of the drug that inhibited 90% of the growth (Munck et al. 2014; Imamovic et al. 2018). All IC_{90} values were generated at least in two technical replicates. If the WT IC_{90} differed $>2$-fold from the WT IC_{90} value established before the ALE started, the IC_{90} test was repeated along with the ancestor WT. No significant (Student’s t-test, $P > 0.05$) differences between the susceptibility of the WT and the media adapted WT were observed. The IC_{90} values were normalized to the media adapted WT IC_{90}. The heatmap presenting the collateral sensitivity and resistance of the single drug evolved lineages (supplementary fig. S2, Supplementary Material online) displays the times increase of the IC_{90} compared with the media adapted WT with a significance level of at least $P < 0.0001$. Significance levels were obtained as described before (Imamovic et al. 2018). Briefly, by comparing the growth data OD_{600} in ten different antibiotic concentrations of all technical and biological replicates adapted to the same drug, with all media adapted technical and biological replicates exposed to the same drug and concentration. Within the natural variation of the samples 3,000 additional data points were computed to identify robust differences among samples. Times increase or decrease in growth compared with the WT were computed to identify robust differences among samples. 

Calculation of Important Variables

Based on the IC_{90} values several calculations were made, that are explained in the following:

The evolvability index is a measure of the final phenotypic adaptation level of isolated drug-pair-evolved lineages to the individual drugs relative to isolated single-drug-evolved lineages (Munck et al. 2014). The evolvability index compares resistance evolution between drug pair and single drug evolved lineages to individual antibiotics. It was calculated as described before (Munck et al. 2014). In short, the following formula was used:

\[
\text{evolvability index} = \frac{(IC_{90A_{AB}}/IC_{90A_{WT}}) + (IC_{90B_{AB}}/IC_{90B_{WT}})}{2}
\]

Two replicate lineages evolved to Amikacin and Nitrofurantion, as well as two replicate lineages evolved to Ciproflaxacin and Doxycycline had evolvability indices above 1000. They displayed extremely high IC_{90} values, when tested to one of the individual drugs (Nitrofurantion/Doxycycline).

As these values were way outside of a reasonable range of resistance they were treated as technical errors and therefore excluded from the entire analysis.

Drug interactions were determined for isolated colonies using a Loew continuous additive model and the IC_{90} as effect level. The Loew continuous additive model was chosen as it assumes additive effects of identical drugs (Munck et al. 2014). This is important as drugs with the same target and drugs from the same drug class were combined in this experiment. The FICI was calculated according to the following formula:

\[
\text{FICI} = \frac{IC_{90A_{WT} + IC_{90B_{WT}}}}{IC_{90A_{WT}} + IC_{90B_{WT}}}
\]

$\omega$ is the molar fraction of A in the drug combination AB. As it was shown that additive effects are robustly detected at a cutoff between 1 and 1.25 (Meletiadis et al. 2010), we applied a low but symmetric cutoff in order to group the drug pairs into synergistic ($<0.75$), antagonistic ($>1.5$), and additive (0.75–1.5) combinations.

The collateral IC_{90} change index was calculated for isolated colonies as described before (Munck et al. 2014). In short, the following formula was used:

\[
\text{collateral IC}_{90} \text{change index} = \frac{IC_{90A_{B}}/IC_{90A_{WT}} + IC_{90B_{A}}/IC_{90B_{WT}}}{2}
\]

All drug pair evolved lineages were grouped into collateral sensitivity ($<0.5$), collateral resistance ($>2$) and neutral (0.5–2) effects according to the collateral IC_{90} change index.

A table including all phenotypic information of the drug pair evolved lineages can be found in the supplement (supplementary table S9, Supplementary Material online).

Whole-Genome Sequencing and Sequence Analysis

1 ml LB in each well of a 96-well, deep-well plate was inoculated from frozen stocks of isolated colonies and grown at 37 °C and 600 r.p.m. overnight. Cells were spun down at 2,000 r.p.m. for 3 min. LB was removed and replaced by DNA shielding buffer (Zymo Research). Samples were sent to BaseClear B.V. for genomic DNA extraction (ZYMO research), Nextera XT library preparation (Illumina) and 125 paired-end whole-genome Illumina HiSeq 2500 sequencing. The resulting fasta reads were used in the following workflow:

(1) Single nucleotide variants (SNPs) and small insertions and deletions (INDELS) were called using CLC Genomics workbench as described before. *Escherichia coli* reads were aligned to the *E. coli* K12 U00096 reference genome. On average, the coverage/base was at least 37-fold. For SNP calling only positions with a phred score of at least 30 at the position where the SNP occurred and at the three neighboring positions were considered. In addition, the SNP had to be detected with a frequency of at least 80%.

(2) CLC Genomics workbench was further used to detect large insertions and deletions (large INDELS) in the reads using the INDEL function at default settings. The resulting
Large insertions were additionally detected by a custom made script used before. The reference genomes of MG1655 as well as all open reading frames were downloaded from the NCBI nucleotide archive and used to cluster all ORFs with cd_hit (Li and Godzik 2006). The cluster cut off was 90% identity and coverage. Afterwards the sequenced reads from this study were quality filtered using the FASTX-Toolkit package with a minimum quality of 30 and blasted against the clustered ORFs with a word size of 16 and an e-value of 0.01. Reads, with >90% coverage mapping continuously to the genome, that mapped to two different clusters with an overlap between 30% and 70% were kept for further analysis. Reads were filtered so they did not cover clusters representing adjacent genes. Finally, large insertions were only counted when they were observed in at least 5 individual reads.

Gene duplications were detected using CLC workbench and a customized script in R as described before (Jahn et al. 2017). Regions > 100 bp of significantly (P < 0.00001) increased coverage according to a Poisson distribution were identified using CLC workbench. The identified regions were mapped to the genome and a gene that was overlapping at least 95% with a region of high coverage was counted as gene duplication.

INDELS that were detected by multiple of the parallel analyses were only counted once. Seven WT lineages adapted to the media were sequenced as a control and mutations as well as duplications found in these lineages were excluded from all lineages as they are likely mutations that have been inserted prior to the experiment or are involved in media adaptations. As no significant (Student’s t-test, P > 0.05) phenotypic difference between the resistance level of the ancestor WT and the media adapted WT lineages were identified, those genetic changes are unlikely to cause antibiotic resistance.

Jaccard’s Distance
The genetic data were used to create a presence absence table for each mutations and lineage. Based on this matrix the Jaccard’s distance was calculated using the jaccardSets function in R from the package bayesbio (McKenzie 2016).

Analysis of Similarity
Based on the genetic data including SNPs, INDELS and gene duplications, a binary presence absence data matrix was created for each lineage and all genes. The matrix was summed for all replicates of the same condition and subsequently used to calculate a dissimilarity matrix with the package “vegan” in R using Euclidian distance (Oksanen et al. 2019). We performed an ANOSIM with the anosim function from the package “vegan” in R for the entire dataset in order to test whether significant differences between groups could be expected (Oksanen et al. 2019). We calculated the same similarity for each drug pair: first, we compared lineages evolved to both single drugs constituting the pair, second, we compared the group of one of the single drug adapted lineages to the drug pair evolved lineages and third, we compared the other single drug evolved lineages to the drug pair evolved ones. Groups were considered to be significantly different when they had a p-value < 0.005 and an R statistics > 0.2. A R statistics of 0.2 has been previously described as measure for mild similarities between groups (Oksanen et al. 2019). The results were aggregated with the package “data.table” (Dowle and Srinivasan 2018).

Data Availability and Code
Genomic data are available in NCBI under the accession number SUB5823083. All phenotypic data and scripts can be provided upon request. For the calculations and different analysis the following R packages have been utilized: “plyr” (Wickham 2011), “dplyr” (Wickham et al. 2018), “tidyr” (Wickham and Henry 2018), “ggplot2” (Wickham 2016), “data.table” (Dowle and Srinivasan 2018), “gdata” (Warnes et al. 2017), “SciViews” (Grosjean 2018), “drc” (Ritz et al. 2015), “scales” (Wickham 2018a), “gridExtra” (Auguie 2017), “cowplot” (Wilke 2018), “stringr” (Wickham 2018b), “ggpubr” (Kassambara 2018), “magrittr” (Bache and Wickham 2014). For figure 1, RawGraphs (Mauri et al. 2017) was used to create the figure. All figures were edited in Abode Illustrator.

Supplementary Material
Supplementary data are available at Molecular Biology and Evolution online.

Acknowledgments
C. Munck and L. Imamovice advised on the panel of individual drugs to use and on the adaptive evolution experiment protocol. O. Bitterlin assisted C. Bradshaw in programming the robot used for preparing plates for the evolution experiment and for IC_{50} determination. In addition, we thank J.J. Collins, A. Porse, D. Kell, J. Yang, A. Lopatkin, S. Li, M.A. Misiakou, and A.S. Hauser for helpful discussions and input on data representation.

This study was supported by the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 642738, MetaRNA as well as from the European Union’s Horizon 2020 (ERC-2014-StG) under grant agreement 638902, LimitMDR. In addition, funding was received from Danish Council for Independent Research, Sapere Aude Program DFF 4004-00213 and from The Novo Nordisk Foundation under NFF grant number: NNF10CC1016517.

Author Contributions
M.O.A.S. and L.J.J. conceived the project. C.B., L.J.J., and D.S. prepared plates used for the adaptive laboratory evolution experiment with help of a Hamilton robot. L.J.J., D.S., and M.J. conducted all experimental work. L.J.J. analyzed and visualized the data. M.M.H.E. analyzed the genomic data for large
insertions and deletions. LJ. wrote the manuscript with input from MOAS.

References

Bache SM, Wickham H. 2014. magrittr: A Forward-Pipe Operator for R. R package version 1.5. Available from: https://CRAN.Rproject.org/package=magrittr.

Bantar C, Vesco E, Heft C, Salamone F, Krayeski M, Gomez H, Coassolo MA, Fiorello A, Franco D, Arango C, et al. 2004. Replacement of broad-spectrum cephalosporins by piperacillin-tazobactam: impact on sustained high rates of bacterial resistance. Antimicrob Agents Chemother. 48(2):392–395.

Barbosa TM, Levy SB. 2000. Differential expression of over 60 chromosomal genes in Escherichia coli by constitutive expression of MarA. J Bacteriol. 182(12):3467–3474.

Bailey SF, Rodrigue N, Kassen R. 2015. The effect of selection environment on the probability of parallel evolution. Mol Biol Evol. 32(6):1436–1448.

Barbosa C, Beadmore R, Schulenburg H, Jansen G. 2018. Antibiotic combination efficacy (ACE) networks for a Pseudomonas aeruginosa model. PLoS Biol. 16(4):e2004356.

Barbosa C, Trebosc V, Kemmer C, Rosenstiel P, Beadmore R, Schulenburg H, Jansen G. 2017. Alternative evolutionary paths to bacterial antibiotic resistance cause distinct collateral effects. Mol Biol Evol. 34(9):2229–2241.

Baym M, Stone LK, Kishony R. 2016. Multidrug evolutionary strategies to reverse antibiotic resistance. Science 351(6268):aad3292.

Beutner EH, Doyle WM, Evanger LC. 1963. Collateral susceptibility of isoniazid-resistant tubercle bacilli to nitrofurans. Am Rev Respir Dis. 88:712–715.

Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. 2005. Effect of aminoglycoside and /lactam combination therapy on /lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis. 41(2):149–158.

Blomberg B, Spinaci S, Fourie B, Laing R. 2001. The rationale for recombinant DNA technology. Bull World Health Organ. 79:61–68.

Bodilsen J, Brouwer MC, Kjærgaard N, Sirks MJ, van der Ende A, Nielsen M, Krogh Johansen H, van de Beek D. 2018. Community-acquired meningitis in adults caused by meningococci in Denmark and The Netherlands. J Infect. 77:125–29.

Brook I. 1989. Inoculum effect. Rev Infect Dis. 11(3):361–368.

Bueno ML, Dexter KG, Pennington RT, Pontara V, Neves DM, Ratter JA, de Oliveira-Filho AT. 2018. The environmental triangle of the Cerrado Domain: ecological factors driving shifts in tree species composition between forests and savannas. J Ecol. 106(5):211–220.

Chevereau G, Bollenbach T. 2015. Systematic discovery of drug interaction mechanisms. Mol Syst Biol. 11:807.

Cohen SP, Häschler H, Levy SB. 1993. Genetic and functional analysis of the multiple antibiotic resistance (mar) locus in Escherichia coli. J Bacteriol. 175(5):1484–1492.

de Evgrafov MR, Gumpert H, Munck C, Thomsen TT, Sommer MOA. 2015. Collateral resistance and sensitivity module evolution of high-level resistance to drug combination treatment in Staphylococcus aureus. Mol Biol Evol. 32(5):1175–1185.

Dowle M, Srinivasan A. 2018. datatable: Extension of ‘data.frame’. R package version 1.118. Available from: https://CRAN.R-project.org/package=datatable.

Gonzalez PR, Pesesky MW, Bouley R, Ballard A, Biddy BA, Suckow MA, Wolter WR, Schroeder VA, Burnham C-AD, Mobashery S, et al. 2015. Synergistic, collaterally sensitive /lactam combinations suppress resistance in MRSA. Nat Chem Biol. 11(11):855–861.

Grojean P. 2018. SciViews-R. UMONS, Mons, Belgium. Available from: http://www.sciviews.org/SciViews-R.

Hegrenes M, Shores N, Damian D, Hartl D, Kishony R. 2008. Accelerated evolution of resistance in multidrug environments. Proc Natl Acad Sci USA. 105(37):13977–13981.

Imamovic L, Ellabaan MMH, Daniels Machado AM, Citerio L, Wulf T, Molin S, Krogh Johansen H, Sommer MOA. 2018. Drug-Driven phenotypic convergence supports rational treatment strategies of chronic infections. Cell 172(1–2):1211–134.e14.

Imamovic L, Sommer MOA. 2013. Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. Sci Transl Med. 5(204):204ra132.

Jahn LJ, Munck C, Ellabaan MMH, Sommer MOA. 2017. Adaptive laboratory evolution of antibiotic resistance using different selection regimes lead to similar phenotypes and genotypes. Front Microbiol. 8.

Jahn LJ, Porse A, Munck C, Simon D, Volkova S, Sommer MOA. 2018. Chromosomal barcoding as a tool for multiplexed phenotypic characterization of laboratory evolved lineages. Sci Rep. 8(1):6961.

Jansen G, Barbosa C, Schulenburg H. 2013. Experimental evolution as an efficient tool to dissect adaptive paths to antibiotic resistance. Drug Resist Update 16(6):96–107.

Jolivet-Gougeon A, Kovacs B, Le Gall-David S, Le Bars H, Bousarghin L, Bonnare-Mallet M, Lobel B, Guillé F, Soucy C-J, Tenke P. 2011. Bacterial hypermutation: clinical implications. J Med Microbiol. 60(5):563–573.

Kassambara A. 2018. ggplot2: Based Publication Ready Plots. R package version 0.2. Available from: https://CRAN.R-project.org/package=ggpubr.

Keeney D, Ruzin A, McAleeese F, Murphy E, Bradford PA. 2008. Mar-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli. J Antimicrob Chemother. 61(1):46–53.

Laehnemann D, Peira-Müller R, Rosenstiel P, Beadmore R, Jansen G, Schulenburg H. 2014. Genomics of rapid adaptation to antibiotics: convergent evolution and scalable sequence amplification. Genome Biol Evol. 6(6):1287–1301.

Lázár V, Pal Singh G, Spohn R, Nagy I, Horváth B, Hryman M, Busa-Fekete R, Bogos B, Méhi O, Cörgö B, et al. 2013. Bacterial evolution of antibiotic hypersensitivity. Mol Syst Biol. 9(1):700–700.

Lee HH, Molla MN, Cantor CR, Collins JJ. 2010. Bacterial charity work leads to population-wide resistance. Nature 467(7311):82–85.

Leibovici L, Paul M, Poznanski O, Drucker M, Samra Z, Konigsberger H, Pitlik SD. 1997. Monotheraphy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother. 41(5):1127–1133.

Levin-Reisman I, Ronin I, Gelen O, Brains I, Shoresh N, Balaban NQ. 2017. Antibiotic tolerance facilitates the evolution of resistance. Science 355(6327):826–830.

Li W, Godzik A. 2006. Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences. Bioinformatics 22(13):1658–1659.

Lipsey M, Castegren M, Furebring M, Spjölin J. 2018. Should the aminoglycoside /lactam combination be abandoned in all severely ill patients with presumed gram-negative infection? Clin Infect Dis. 66(3):480–6591.

Lipsitch M, Levin BR. 1997. The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother. 41(2):363–373.

Luepke KH, Suda KJ, Boucher H, Russo RL, Bonney MW, Hunt TD, Mohr JF. 2017. Past, present, and future of antibacterial economics: increasing bacterial resistance, limited antibiotic pipeline, and societal implications. Pharmacotherapy 37(1):71–84.

MacPherson A, Nuismer SL. 2017. The probability of parallel genetic evolution from standing genetic variation. J Evol Biol. 30(2):326–337.

Mauri M, Elli T, Caviglia G, Uboldi G, Azzi M. 2017. RAWGraphs: a visualisation platform to create open outputs. Proceedings of the 12th Biannual Conference of Italian SIGCHI Chapter. New York: ACM. p. 281–285. Available from: https://doi.org/10.1145/3125573.3125585.

McKenzie A. 2016. bayesio: Miscellaneous Functions for Bioinformatics and Bayesian Statistics.

Meletiadis J, Pourmara S, Roilides E, Walsh TJ. 2010. Defining fractional inhibitory concentration index cutoffs for additive interactions
based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro–in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrob Agents Chemother. 54(2):602–609.

Minato Y, Dawadi S, Kordus SL, Sivanandam A, Aldrich CC, Baughn AD. 2018. Mutual potentiation drives synergy between trimethoprim and sulfamethoxazole. Nat Commun. 9(1):3003.

Munck C, Cumpert HK, Wallin AIN, Wang HH, Sommer MOA. 2014. Prediction of resistance development against drug combinations by collateral responses to component drugs. Sci Transl Med. 6(262):262ra156.

Oksanen J, Blanchet FG, Friendly M, Kindt R, Legendre P, McGlinn D, Minchin PR, O’Hara RB, Simpson GL, Solymos P, et al. 2014. vegan: Community Ecology Package. R package version 2.5-5. Available from: https://CRAN.R-project.org/package=vegan.

Okusu H, Ma D, Nikaido H. 1996. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple antibiotic-resistance (Mar) mutants. J Bacteriol. 178(1):306–308.

Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L. 2014. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev. 2014(1):CD003344.

Pena-Miller R, Laehnemann D, Jansen G, Fuentes-Hernandez A, Ritz C, Baty F, Streibig JC, Gerhard D. 2015. Dose–response analysis using R. PLoS One 10(12):e0146021.

Pfleger B, Bührer C, Jörres A, Manhal T, Schaufelberger M, Schmidli J. 2002. Critically ill patients with sepsis in the intensive care unit: a population-based study. Crit Care Med. 30(5):1269–1276.

Pomposiello PJ, Bennik MH, Demple B. 2001. Genome-wide transcriptional profiling of the Escherichia coli responses to superoxide stress and sodium salicylate. J Bacteriol. 183(13):3890–3902.

Skorup P, Maudsdotter L, Lipcsey M, Castegren M, Larsson A, Jonsson A-B, Sjölin J. 2014. Beneficial antimicrobial effect of the addition of an aminoglycoside to a β-lactam antibiotic in an E. coli porcine sepsis model. PLoS One 9(2):e90441.

Stokes JM, MacNair CR, Ilyas B, French S, Côté J-P, Bouwman C, Farha MA, Sieron AO, Whitfield C, Coombes BK, et al. 2017. Pentamidine sensitizes Gram-negative pathogens to antibiotics and overcomes acquired colistin resistance. Nat Microbiol. 2:17028.

Suzuki S, Horinouchi T, Furusawa C. 2015. Suppression of antibiotic resistance acquisition by combined use of antibiotics. J Bacteriol. 64(4):489–499.

Tepekule B, Uecker H, Derungs I, Frenoy A, Bonhoeffer S. 2017. Modeling antibiotic treatment in hospitals: a systematic approach shows benefits of combination therapy over cycling, mixing, and mono-drug therapies. PLoS Comput Biol. 13(9):e1005745.

Torella JP, Chait R, Kishory R. 2010. Optimal drug synergy in antimicrobial treatments. PLoS Comput Biol. 6(6):e1000796.

Tyers M, Wright GD. 2019. Drug combinations: a strategy to extend the life of antibiotics in the 21st century. Nat Rev Microbiol. 17(3):143–155.

Ventola CL. 2015. The antibiotic resistance crisis. Pharm Ther. 40:277–283.

Wahl LM, Gerrish PJ, Saika-Voivod I. 2002. Evaluating the impact of population bottlenecks in experimental evolution. Genetics 162(2):961–971.

Wames GR, Bolker B, Gorjanc G, Grohendieck E, Korosec A, Lumley T, MacQueen D, Magnusson A, Rogers J, et al. 2017. gdata: Various R Programming Tools for Data Manipulation. R package version 2.18.0. Available from: https://CRAN.R-project.org/package=gdata.

Wickham H. 2011. The split-apply-combine strategy for data analysis. J Stat Soft. 40(1):1–29. Available from: http://www.jstatsoft.org/v40/i01/

Wickham H. 2016. ggplot2: elegant graphics for data analysis. New York: Springer-Verlag.

Wickham H. 2018a. strings: Simple, Consistent Wrappers for Common String Operations. R package version 1.3.1. Available from: https://CRAN.R-project.org/package=stringr.

Wickham H. 2018b. scales: Scale Functions for Visualization. R package version 1.0.0. Available from: https://CRAN.R-project.org/package=scales.

Wickham H, François R, Henry L, Müller K. 2018. dplyr: A Grammar of Data Manipulation. R package version 0.8.0. Available from: https://CRAN.R-project.org/package=dplyr.

Wickham H, Henry L. 2018. tidyr: Easily Tidy Data with ‘spread()’ and ‘gather()’ Functions. R package version 0.8.2. Available from: https://CRAN.R-project.org/package=tidyr.

Wilke CO. 2018. cowplot: Streamlined Plot Theme and Plot Annotations for ‘ggplot2’. R package version 0.9.3. Available from: https://CRAN.R-project.org/package=cowplot.

Wong A. 2017. Episiasis and the evolution of antimicrobial resistance. J Glob Antimicrob Resist. 10:1–5.

Woodford N, Ellington MJ. 2007. The emergence of antibiotic resistance by mutation. Clin Microbiol Infect. 13(1):5–18.

World Health Organization, and Global Tuberculosis Programme 2016. WHO treatment guidelines for drug-resistant tuberculosis: 2016 update.

Yu EW, Aires JR, Nikaido H. 2003. AcrB multidrug efflux pump of Escherichia coli: composite substrate-binding cavity of exceptional flexibility generates its extremely wide substrate specificity. J Bacteriol. 185(19):5657–5664.